Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer

Prostate cancer (PCa) accounted for over 300 000 deaths world-wide in 2018. Most of the PCa deaths occurred due to the aggressive castration-resistant PCa (CRPC). Since the androgen receptor (AR) and its ligands contribute to the continued growth of androgen-dependent PCa (ADPCa) and CRPC, AR has be...

Descripción completa

Detalles Bibliográficos
Autor principal: Narayanan, Ramesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Second Military Medical University 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385518/
https://www.ncbi.nlm.nih.gov/pubmed/32742927
http://dx.doi.org/10.1016/j.ajur.2020.03.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385518/
https://www.ncbi.nlm.nih.gov/pubmed/32742927
http://dx.doi.org/10.1016/j.ajur.2020.03.002

Ejemplares similares